Table 2.
CLND Site | Control Group | Group 1 | Group 2 | ||
---|---|---|---|---|---|
N | N | p | N | p | |
Axilla | 7/51 (13.7%) | 0/8 (0.0%) | / | 0/11 (0.0%) | / |
Groin | 22/69 (31.9%) | 1/15 (7.7%) | 0.05 | 1/18 (5.6%) | 0.02 |
TOT | 29/120 (24.2%) | 1/23 (4.3%) | 0.03 | 1/29 (3.5%) | 0.01 |
CLND Site | Control Group | Group 1 | Group 2 | ||
---|---|---|---|---|---|
N | N | p | N | p | |
Axilla | 7/51 (13.7%) | 0/8 (0.0%) | / | 0/11 (0.0%) | / |
Groin | 22/69 (31.9%) | 1/15 (7.7%) | 0.05 | 1/18 (5.6%) | 0.02 |
TOT | 29/120 (24.2%) | 1/23 (4.3%) | 0.03 | 1/29 (3.5%) | 0.01 |